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Abstract:  
 
The gram-scale isolation of the major flavonolignan diastereoisomers from milk thistle (Silybum 
marianum) extract provided an entré into the isolation of two related analogs that are present in 
extremely minute quantities. The isolation and structure elucidation of these two new 
compounds, which we have termed isosilybin C and isosilybin D due to their structural 
similarities to isosilybin A and isosilybin B, respectively, afforded a preliminary analysis of 
structure-activity relationships toward prostate cancer growth, survival, and apoptotic endpoints. 
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Article: 
 
In previously reported studies [1], our team performed the gram-scale isolation of four key 
flavonolignan diastereoisomers (silybin A, silybin B, isosilybin A, and isosilybin B) from milk 
thistle [Silybum marianum(L.) Gaertn. (Asteraceae)]. Presently, these materials are undergoing 
evaluation, both in vitro and in vivo, for their prostate cancer chemopreventive, antiproliferative, 
and pro-apoptotic properties [2-5]. In that earlier work, over 250 g of milk thistle extract [termed 
‘silymarin’; see [6] for a review on the nomenclature of milk thistle components] were processed 
through several rounds of chromatography to yield 3 to 4 grams of each diastereoisomer [1]. 
Based on the distinctive UV profile of this class of flavonolignans, and retention times that were 
longer than the most retained compound, isosilybin B, in reverse phase HPLC, we hypothesized 
that some of the side fractions contained constituents of a similar structural type present in low 
yields. As isosilybin B and, to a lesser extent, isosilybin A seem to be the most potent in various 
prostate cancer chemopreventive and antiproliferative activity assays [2-5, 7] the evaluation of 
these new compounds in vitrocould expand our knowledge of the structure-activity relationships 
of flavonolignans against this type of neoplasm. 
Compound 1 was isolated as a yellow film. The molecular formula, determined by HRESIMS, 
was C25H22O10, giving an index of hydrogen deficiency of 15. This is the same molecular 
formula of flavonolignan diastereoisomers from milk thistle [8, 9]. The 1D NMR data 
of 1 showed signals typical of atrans-3-hydroxyflavanone moiety with hydroxyl substitutions at 
positions C-5 and C-7 (Table 1). Additional aromatic proton and carbon signals, as well as two 
oxygenated methines, an oxymethylene, and a methoxy signal also indicated a flavonolignan 
structural type [8, 9]. However, the lignan-derived third aromatic ring in1 displayed a 1,3,5-
substitution pattern, as evidenced by coupling constants (J2″=J4″=J6″=2 Hz), positioning a 
hydroxyl group at C-5″ and a methoxy group at C-3″. Alternatively, the major flavonolignans, 
silybin A (3), silybin B (4), isosilybin A (5), and isosilybin B (6) (Figure 1), have a 1,3,4- 
substitution pattern. HMBC data revealed that the regiochemistry of 1 (Figure 2) was similar to 
that of compounds 5 and 6. 
 
 
 
Figure 1. Structures of flavonolignans from milk thistle. 
 
 
 
Figure 2. Key HMBC correlations in 1 
 
 
 
Table 1. NMR data of compounds 1 and 2 in DMSO-d6 
 
The spectroscopic and spectrometric data of 2 were nearly identical to those of 1. The major 
differences were discernable in the CD (Figure 3) and optical rotation data, where 1 and 2 had 
values of equal magnitude but opposite sign. The trivial names isosilybin C (2) and isosilybin D 
(1) were assigned to these new compounds, given their stereochemical similarities to isosilybin 
A (5) and isosilybin B (6), respectively. 
 
 
 
Figure 3. CD data of compounds 1 and 2; the CD data for compounds 3-6 has been published 
previously [8]. 
 
Compounds 1-6 were evaluated for antiproliferative/cytotoxic activity against a panel of three 
prostate cancer cell lines. Compounds 1 and 2 had decreased activity, relative to the well studied 
compounds 3-6 [2-4, 8]. This suggested that an ortho relationship for the hydroxyl and methoxy 
substituents (in 3-6) was more favorable than the meta relationship for the same substituents 
(in 1 and 2), although other structural features may also be important. The configuration that was 
most similar to isosilybin B (6), being compound 1, was more potent, as we predicted. Activity 
for the multicomponent mixture from which these compounds were isolated, silymarin, was also 
examined as a positive control. Medicinal chemistry studies are ongoing to probe the structure-
activity relationships in the flavonolignan series further. 
 
MATERIALS AND METHODS 
 
Optical rotations, IR spectra, UV spectra, and CD spectra were recorded on a Rudolph Research 
Autopol III automatic polarimeter, a Nicolet Avatar 360 FT-IR, a Varian Cary 3 UV-Vis 
spectrophotometer, and an Aviv Circular Dichroism Stopped Flow Model 202, respectively. 
NMR experiments were performed on a Varian-500 spectrometer with TMS as an internal 
standard. High resolution mass spectrometry data were acquired via an Agilent G1969A MSD-
TOF instrument (Santa Clara, CA). Internal standards were infused via the reference nebulizer 
simultaneous with sample analysis, and data were acquired with reference mass correction 
enabled. Data were processed and lists of possible molecular formulae were generated using 
Analyst QS (Applied Biosystems; Foster City, CA). HPLC-grade solvents were purchased from 
Burdick & Jackson (Muskegon, MI, USA). Reverse Phase-HPLC was carried out on Varian 
Prostar HPLC systems (Walnut Creek, CA, USA) using YMC ODS-A (5 μm; 250 × 25 mm; 
Waters; Milford, MA, USA) columns, as described previously [1]. 
 
Powdered extract (1 kg; Product No. 345066, Lot No. 37501) of the seeds (achenes) of Silybum 
marianum(L.) Gaertn. was obtained from Euromed, S.A. (Barcelona, Spain), which is a part of 
the Madaus Group (Cologne, Germany) [1]. This extract (silymarin) was used also as a positive 
control for the antiproliferative/cytotoxic activity experiments, since it has been evaluated 
extensively in biological assays [4,5, 7, 10, 11]. Our team published the chemical profile of this 
extract previously [7]. Compounds 3-6 were isolated from this same extract and their purities 
were as described [1]. 
 
The processing of milk thistle extract to yield gram quantities of flavonolignans was described in 
detail previously [1]. In the process of isolating gram quantities of isosilybin B (6), which 
retained the longest on RP-HPLC of the seven major flavonolignan diastereoisomers [1], 
numerous fractions were obtained that contained minor compounds that eluted after 6. 
Compounds 1 and 2 were isolated from a pool of these fractions. Briefly, a pool (1029 mg) of 
later eluting fractions were purified using the reverse phase column and equipment described 
above via an isocratic system of 50:50 MeOH:H2O over 90 minutes. Two fractions that were 
enriched in 1 and 2 were pooled (204 mg; pool B), and Figure 4 (Supporting 
Information) displays the chromatogram of pool B via analytical HPLC; the elution profile of 
isosilybin A (5), isosilybin B (6), isosilybin D (2), and isosilybin C (1), respectfully, is 
discernable, showing the longer retention time of the later two. An isocratic system of 50:50 
MeOH:H2O over 100 minutes was used to purify this pool. From this, four fractions were pooled 
(95 mg) and rechromatographed via the same solvent system over 115 minutes. Compound 1 (21 
mg) was isolated in >99% purity. A single fraction (14 mg) was rechromatographed via the same 
system over 120 minutes to isolate compound 2 (3 mg) in >99% purity. 
 
Isosilybin D (1): Yellow film; [α]D: +11 (c 0.02, MeOH); UV (MeOH) λmax (log ε) 288 (0.87), 
230 (0.95), 212 (1.24); CD (MeOH) λext (Δε) 326 (+2.9), 295 (−13.8), 242 (+18.7); 
HRESIMS m/z = 483.1290 [M+H]+ (calcd for C25H23O10, 483.1285). 1H and 13C NMR data, 
see Table 1; HMBC: H-2 → C-3, 4, 9, 1′, 2′, 6′; H-3 → C-2, 4, 1′; H-6→ C-5, 7, 8, 10; H-8→ C-
6, 7, 9, 10; H-2′→ C-2, 1′, 3′, 4′, 6′; H-5′→ C-1′, 3′, 4′, 6′; H-6′→ C-2, 1′, 2′, 4′, 5′; H-α→ C-3′, 
β, γ, 1″; H-β → C-4′, α, γ, 1″, 2″, 6″; H-γ → C- α , β. 
 
Isosilybin C (2). Yellow film; [α]D = −13 (c 0.003, MeOH); UV (MeOH) λmax (log ε) 288 (1.14), 
230 (1.33), 212 (1.60); CD (MeOH) λext (Δε) 326 (+0.9), 294 (−13.2), 242 (−13.2); 
HRESIMS m/z 483.1293 [M+H]+ (calcd for C25H23O10, 483.1285). H and 13C NMR data, 
see Table 1; HMBC:H-2 → C-3, 4, 9, 1′, 2′, 6′; H-3 → C-2, 4, 1′; H-6→ C-5, 7, 8, 10; H-8→ C-
6, 7, 9, 10; H-2′→ C-2, 1′, 3′, 4′, 6′; H-5′→ C-1′, 3′, 4′, 6′; H-6′→ C-2, 1′, 2′, 4′, 5′; H-α→ C-3′, 
β, γ, 1″; H-β → C-4′, α, γ, 1″, 2″, 6″; H-γ → C- α , β. 
 
Compounds were tested for antiproliferative/cytotoxic activity using modifications of a 
published procedure [7]. Prostate cancer cell lines were obtained from the American Type 
Culture Collection (Manassas, VA): DU145 (HTB-81, an androgen-independent line derived 
from a central nervous system metastasis of prostate adenocarcinoma), PC-3 (CRL-1435, an 
androgen-independent line derived from a bone metastasis of prostate adenocarcinoma), and 
LNCaP (CRL-1740, an androgen-dependent line derived from a lymph node metastasis of 
prostate adenocarcinoma). All cell lines were cultured and maintained exactly as described 
previously [7], except for LNCaP cells, which were maintained at an initial density of 
2×106 cells per 75 cm2flask in 30 mL medium. 
 
For cytotoxicity experiments, logarithmically growing cells were seeded at either 1500 cells per 
well (DU145) or 3000 cells per well (PC-3 and LNCaP) in 96-well plates in 50 μL of medium 
and allowed to attach to plate overnight. The following day, stock solutions of pure compounds 
were prepared in DMSO at 100 mM and diluted into RPMI 1640 (Life Technologies/Invitrogen, 
Carlsbad, CA) at twice the intended final concentration of 5, 10, 15, 30, 60, 90, or 120 μM. A 50 
μL aliquot of each compound in medium was added to each well (in triplicate for each final 
concentration). After incubating for five days, 10 μL of the mitochondrial dehydrogenase 
substrate WST-8/PMS [Cell Counting Kit-8 (CCK-8), Dojindo, Gaithersburg, MD] was added to 
each well and incubated 2 h further. Cell-free wells of medium were incubated similarly to 
correct for nonenzymatic hydrolysis of the substrate to its formazan product. Mitochondrial 
respiratory activity was quantified by spectrophotometry as described previously [7] and cellular 
survival expressed as a percentage relative to the corrected control values. 
 
 
Table 2. IC50 values in μM reported as the average ± SD from three dose-response experiments. 
Within each experiment, compounds were assessed in triplicate. IC50 values were calculated by 
linear regression.Parentheses indicate percent survival at 120 μM. Data for silymarin are 
provided as a positive control, given its extensive investigation for activity against human 
prostate cancer in vitro and in vivo; the molarity calculation for this multicomponent mixture was 
as described [7]. 
SUPPLEMENTARY MATERIAL 
 
 
 
Figure 4 (Supporting Information). Chromatogram (284 nm) of pool B showing the elution 
order of isosilybin A (5), isosilybin B (6), isosilybin D (1), and isosilybin C (2). The sample (~1 
mg/mL dissolved in MeOH, 5µL injected) was analyzed using a YMC ODS-A (5 µm; 250 × 4.6 
mm; Waters; Milford, MA, USA) column eluted with 50:50 MeOH:H2O isocratically for 23 min 
using the instrument described in the Materials and Methods. These methods were used for all 
other analytical experiments performed for this study. 
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